DS-1123 / Daiichi Sankyo - LARVOL DELTA

Study of DS-1123a in Advanced Solid Tumours (clinicaltrials.gov) - P1; N=27; Completed; Sponsor: Daiichi Sankyo Co., Ltd.; Active, not recruiting ➔ Completed; Trial primary completion date: Jul 2018 ➔ Nov 2017

Trial completion • Trial primary completion date • Biosimilar • Oncology • Solid Tumor

DS-Screen: Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer population. (ASCO-GI 2020) - "Moreover, eligible patients for the clinical trials of DS-1123 or DS-8201, which are FGFR2- or HER2-targeting anti-cancer agent respectively, were screened. This study showed insights into the expression status of FGFR2 and HER2 in GC and CRC as a large-scale prospective analysis. Seven patients who had no standard therapy could access exploratory new drug based on targetable agents through this study. Clinical trial information: 163380."

Clinical • FGFR2 • HER-2 • KRAS • NRAS